Wyeth Applauds Governments' Decision to Fund Pneumococcal Vaccine for Developing Countries

จันทร์ 12 กุมภาพันธ์ 2550 เวลา 10:16 น.

COLLEGEVILLE,Pennsylvania--12 Feb--PRNewswire-AsiaNet/InfoQuest

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), welcomes the decision by donor countries to focus on the importance of pneumococcal disease and to launch a pilot Advanced Market Commitment, which will help to bring the pneumococcal conjugate vaccine to developing countries.

"This financial pledge brings much needed attention to the global burden of pneumococcal disease," says Bernard Poussot, President, Chief Operating Officer and Vice Chairman, Wyeth. "We join the International Federation of

Pharmaceutical Manufacturers and Associations and the global community in commending the donor countries, and look forward to cooperating with international partners with the goal of helping to protect children in developing countries against the potentially devastating consequences of pneumococcal disease."

Wyeth is committed to helping to protect infants and young children against pneumococcal disease and currently markets the only pneumococcal conjugate vaccine, PREVENAR(TM), Pneumococcal Saccharide Conjugated Vaccine, Adsorbed, which has been incorporated into many childhood immunization programs around the world and has had a significant public health impact.

Recently, the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE), advocated for priority inclusion of PREVENAR in national immunization programs around the world. SAGE recommended that the vaccine be incorporated into immunization programs now, in view of the demonstrated vaccine efficacy and high disease burden, to help substantially reduce

mortality and morbidity.

In addition, Wyeth is now developing a 13-valent pneumococcal conjugate vaccine that targets additional serotypes. This investigational vaccine is currently undergoing clinical development and would potentially offer broader coverage against pneumococcal disease.

About Pneumococcal Disease

Pneumococcal disease is caused by the bacterium S. pneumoniae, and describes a group of illnesses, including bacteremia/sepsis, meningitis, pneumonia and otitis media. Pneumococcal disease affects both children and adults and is a major cause of death and illness worldwide. The WHO estimates that pneumococcal disease results in up to one million deaths each year in children less than 5 years of age worldwide. Further, according to WHO, pneumococcal disease is the number one vaccine-preventable cause of death in

children less than 5 years of age worldwide.

Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty

of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third party-payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business

operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk

Factors." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or

otherwise.

SOURCE: Wyeth Pharmaceuticals

CONTACT: Natalie de Vane, +1-484-865-5139, or Valerie Bomberger,

+1-484-865-4188, both of Wyeth Pharmaceuticals; or Investor Contact: Justin

Victoria of Wyeth, +1-973-660-5340/

Web site: http://www.wyeth.com/

(WYE)

--Distributed by AsiaNet ( www.asianetnews.net )--

ข่าวWyeth Pharmaceuticals+o:healวันนี้

Wyeth Receives Positive Opinion from European Regulators for its 13-valent Pneumococcal Candidate Vaccine for Infants and Young Children

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company's pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent Adsorbed]). The CHMP recommends approval of Prevenar 13 for active immunization of children aged 6 weeks to 5 years for the prevention of invasive pneumococcal disease, as well as

28 กันยายน 2552 10:47 น.

วัคซีน Prevenar 13* ของไวเอทได้รับการอนุมัติให้ใช้สำหรับป้องกันโรคติดเชื้อนิวโมคอคคัสในทารกและเด็กเล็กเป็นครั้งแรก

ชิลีให้การอนุมัติวัคซีน Prevenar 13 เพื่อป้องกันโรคติดเชื้อนิวโมคอคคัสในทารกและเด็กเล็กเป็นครั้งแรก ไวเอท ฟาร์มาซูติคอลส์ (Wyeth Pharmaceuticals) ซึ่งเป็นบริษัทในเครือไวเอท (NYSE: WYE)... ก.ค. 52

Wyeth's Prevenar 13* Receives First Approval

-Chile Grants First Approval of Prevenar 13 for the Prevention of Pneumococcal Disease in Infants and Children- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the Chilean Ministry of Health, MINSAL (Ministerio de Salud), has... ก.ค. 52

ข้อมูลเบื้องต้นจากการวิจัย 2 ฉบับเผยประสิทธิภาพของการใช้ยา Neratinib ร่วมกับยา Trastuzumab และร่วมกับยา Paclitaxel ในผู้ป่วยมะเร็งทรวงอก HER-2 ขั้นรุนแรง

ไวเอท ฟาร์มาซูติคอลส์ (Wyeth Pharmaceuticals) ซึ่งเป็นบริษัทในเครือไวเอท (NYSE: WYE) ประกาศข้อมูลเบื้องต้นจากสองการวิจัยสำคัญ หนึ่งคือการประ... มิ.ย. 52

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one... มิ.ย. 52

สำนักงานอาหารและยาสหรัฐรับพิจารณา Prevnar 13 ก่อนอนุมัติเป็นยาตัวใหม่สำหรับโรคติดเชื้อนิวโมคอคคัส

ไวเอท ฟาร์มาซูติคอลส์ (Wyeth Pharmaceuticals) ซึ่งเป็นบริษัทในเครือไวเอท (NYSE: WYE) ประกาศว่า องค์การอาหารและยาสหรัฐ (FDA) กำลังอยู่ระหว่างพิจารณาสถานะยาให้กับ Prevnar 13* ซึ่งเป็นวัคซีนป้องกัน 13 ... พ.ค. 52

FDA Grants Priority Review Status to Prevnar 13 Marketing Application

Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration ... พ.ค. 52

ไวเอท เปิดตัวพันธมิตรใหม่ในโครงการ Twinning Program ขององค์การฮีโมฟีเลียโลก

ไวเอทและชุมชนร่วมสานต่อปณิธานการดูแลผู้ป่วยในวันฮีโมฟีเลียโลก ในวาระครบรอบ 20 ปีของวันฮีโมฟีเลยโลก ไวเอท ฟาร์มาซูติคอลส์ (Wyeth Pharmaceuticals) บริษัทในเครือ ไวเอท (NYSE: WYE) จับมือกับองค์การฮีโมฟีเลียโลก (World Federation... เม.ย. 52

New Partnerships Added to World Federation of Hemophilia Twinning Program

Wyeth and Advocacy Community Mark Continued Commitment to Patient Care on World Hemophilia Day In honor of the twentieth Anniversary of World Hemophilia Day, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), together with... เม.ย. 52

ไวเอท ยื่นเรื่องต่อองค์การอาหารและยาสหรัฐเพื่อขอจำหน่ายวัคซีนป้องกัน 13 โรคที่เกิดจากการติดเชื้อนิวโมคอคคัสในทารกและเด็กเล็ก

วัคซีนดังกล่าวถูกพัฒนาขึ้นเพื่อป้องกัน 13 โรคติดเชื้อนิวโมคอคคัสที่แพร่หลายที่สุดในหมู่ทารกและเด็กเล็ก ไวเอท ฟาร์มาซูติคอลส์ (Wyeth Pharmaceuticals) ซึ่งเป็นบริษัทในเครือไวเอท ... เม.ย. 52